In vitro and Numerical Simulation of Blood Removal from Cerebrospinal Fluid: Comparison of Lumbar Drain to Neurapheresis Therapy

Mohammadreza Khani

University of Idaho

Lucas Sass

University of Idaho

M. Keith Sharp

University of Louisville

Aaron McCabe

minnetronix medical

Laura Zitella Verbick

minnetronix medical

Shivanand Lad

Duke University

bryn martin (✉ brynm@uidaho.edu)

<https://orcid.org/0000-0003-1234-7880>

Research

Keywords: Computational fluid dynamics, In-vitro model, Subarachnoid hemorrhage, 61 Neurapheresis therapy, Cerebrospinal fluid filtration, Multiphase simulation

Posted Date: January 15th, 2020

DOI: <https://doi.org/10.21203/rs.2.20844/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Fluids and Barriers of the CNS on March 16th, 2020. See the published version at <https://doi.org/10.1186/s12987-020-00185-5>.

Title

In vitro and Numerical Simulation of Blood Removal from Cerebrospinal Fluid:
Comparison of Lumbar Drain to Neurapheresis Therapy

Authors

Mohammadreza Khani¹, Lucas R. Sass¹, M. Keith Sharp², Aaron R. McCabe³, Laura M.
Zitella Verbick³, Shivanand P. Lad⁴, Bryn A. Martin^{1*}

¹Department of Biological Engineering, The University of Idaho 875 Perimeter Drive, MS
0904, Moscow, Idaho 83844-0904

²Department of Mechanical Engineering, University of Louisville, 332 Eastern Pkwy,
Louisville, KY 40292

³Minnetronix Neuro, Inc., 1635 Energy Park Dr, St Paul, MN 55108

⁴Department of Neurosurgery, Duke University School of Medicine, 3100 Tower Blvd,
Durham, NC 27707

***Corresponding author:**

Department of Biological Engineering, University of Idaho 875 Perimeter Drive, MS
0904, Moscow, Idaho 83844-0904

Tel: 208-885-1030 Email: brynm@uidaho.edu

Abstract

Background: Blood removal from cerebrospinal fluid (CSF) in post-subarachnoid hemorrhage patients may reduce the risk of related secondary brain injury. We formulated a computational fluid dynamics (CFD) model to investigate the impact of a dual-lumen catheter-based CSF filtration system, called Neurapheresis™ therapy, on blood removal from CSF compared to lumbar drain.

Methods: A subject-specific multiphase CFD model of CSF system-wide solute transport was constructed based on MRI measurements. The Neurapheresis catheter geometry was added to the model within the spinal subarachnoid space. Neurapheresis flow aspiration and return rate was 2.0 and 1.8 (mL/min), versus 0.2 (mL/min) drainage for lumbar drain. Blood was modeled as a bulk fluid phase within CSF with a 10% initial tracer concentration and identical viscosity and density as CSF. Subject-specific oscillatory CSF flow was applied at the model inlet. The dura and spinal cord geometry were considered to be stationary. Spatial-temporal tracer concentration was quantified based on time-average steady-streaming velocities throughout the domain under Neurapheresis therapy and lumbar drain. To help verify CFD results, an optically clear in vitro CSF model was constructed with fluorescein used as a blood surrogate. Quantitative comparison of numerical and in vitro results was performed by linear regression of spatial-temporal tracer concentration over 24-hours.

Results: After 24-hours, tracer concentration was reduced to 4.9% under Neurapheresis therapy compared to 6.5% under lumbar drain. Tracer clearance was most rapid between the catheter aspiration and return ports. Neurapheresis therapy was found to have a greater impact on steady-streaming compared to lumbar drain. Steady-streaming in the

cranial SAS was ~50X smaller than in the spinal subarachnoid space for both cases. CFD results were strongly correlated with the in vitro spatial-temporal tracer concentration under Neurapheresis therapy ($R^2=0.89$ with +2.13% and -1.93% tracer concentration confidence interval).

Conclusion: A subject-specific CFD model of CSF system-wide solute transport was used to investigate the impact of Neurapheresis therapy on tracer removal from CSF compared to lumbar drain over a 24-hour period. Neurapheresis therapy was found to substantially increase tracer clearance compared to lumbar drain. The multiphase CFD results were verified by in vitro fluorescein tracer experiments.

60 **Keywords:** Computational fluid dynamics, In-vitro model, Subarachnoid hemorrhage,
61 Neurapheresis therapy, Cerebrospinal fluid filtration, Multiphase simulation.

62

Background

A detailed understanding of cerebrospinal fluid (CSF) physiologic function may help improve treatment of CSF-related CNS diseases and debilitating neurological conditions. CSF is a clear, colorless fluid that occupies the subarachnoid space (SAS) and the ventricular system within the brain (1). CSF is believed to be primarily produced within the ventricles of the brain by ependymal cells located on the choroid plexus surface and absorbed at the arachnoid granulations located on the surface of the superior sagittal sinus (2). CSF moves with a net flow direction outward from the ventricles to the SAS but also multi-directionally with an oscillatory motion, driven by cardiac and respiratory-related pressure fluctuations and other transient maneuvers (3). CSF serves multiple physiologic roles that continue to be discovered. Some of the roles of CSF include: 1) suspension of the delicate brain tissue by the Archimedes principle making the brain tissue nearly neutrally buoyant, 2) damping of forces that act on the brain tissue due to transient impact (4), 3) providing immunological and biochemical homeostasis for the CNS, and 4) delivery of metabolites and micronutrients to the CNS (1, 5).

The importance of CSF dynamics has been investigated in several CNS diseases that include neuroinflammatory conditions such as multiple sclerosis (6, 7) and neurovascular conditions such as cerebral ischemia (8, 9), traumatic brain injury (10) and subarachnoid hemorrhage (SAH) (11). Delayed ischemia and hydrocephalus following SAH are two of the primary causes of morbidity/mortality due to the presence of blood in the subarachnoid spaces (SAS) (12-14). Therefore, strategies to facilitate the rapid clearance of blood from the SAS may reduce the risk of these complications to patients. Such strategies, including lumbar drain (11, 15), cisternal drainage (16, 17) and cisternal

86 lavages (18, 19), have been studied by a number of investigators, but the exact biological
87 mechanisms responsible for delayed ischemia are not yet clear.

88 NeurapheresisTM therapy (Minnetronix Neuro, Inc., St. Paul, MN) is being
89 investigated as a means to potentially rapidly remove red blood cells from the SAS and
90 consequently decrease the incidence or severity of secondary complications. In brief,
91 Neurapheresis therapy involves aspiration of CSF from the lumbar spinal SAS, filtration
92 of CSF and removal of red blood cells and detritus to a waste bag, and then return of
93 filtered CSF to the SAS at the thoracic spine. The different locations of the aspiration and
94 return ports may facilitate advective bulk movement of CSF between the ports within the
95 SAS. Additional details on Neurapheresis therapy are provided by Khani et al.(20).

96 Computational and in vitro modeling constitute potential methods to study complex
97 transport phenomena occurring during blood clearance from CSF spaces and,
98 subsequently, to improve devices and protocols to treat neural disorders. Clinical trials to
99 develop guidelines for more effective clearance are difficult due to limited availability of
100 subjects and associated study costs. Empirical models limit our ability to investigate CSF
101 filtration technologies, highlighting the need for a computational tool. Human clinical trials
102 of Neurapheresis therapy in SAH patients are being conducted (PILLAR trial (21-23)), but
103 these studies lack real-time visualization of blood distribution and are only able to sample
104 CSF from select locations. Also, in principle, a nonhuman primate experimental model of
105 SAH could be developed, but such studies are expensive, are only available at limited
106 research centers, and do not provide similitude of CSF dynamics to humans (24, 25).

107 Several in vivo, in vitro, and in silico studies have been conducted to better
108 understand Neurapheresis therapy. A rabbit model was used to investigate

Neurapheresis therapy in the context of cryptococcal meningitis. This study showed a 5-log reduction in yeast concentration and 1-log reduction in its polysaccharide antigen over 24-hours. A drawback of the study was that the rabbit model had an extremely small SAS, thus it is unclear how rabbit CSF dynamics compare to humans (26). A study by Tangen et al. (27) presented a computational and in vitro model of SAH clearance from CSF. This study provided information about the potential of CSF filtration to assist with blood removal under different body orientations (i.e., supine versus upright) with an idealized representation of CSF space anatomy. Khani et al. formulated a numerical model to investigate the impact of Neurapheresis therapy on CSF flow velocities in a realistic spinal SAS geometry with subject-specific CSF flow along the spine (20). However, this model did not take into account the intracranial portion of the CSF system and lacked a multiphase fluid mixture of blood and CSF.

While the previous studies provided insight into Neurapheresis therapy, they had the following important limitations: a) they lacked realistic system-wide CSF geometry, b) they did not consider the multi-phase solute transport within the CSF, c) they were conducted over relatively short time periods, d) they utilized animal models that have different CSF dynamics than humans, and/or e) they lacked numerical model solution verification. This study seeks to address these limitations by formulating a multi-phase numerical model of CSF system-wide solute transport within an anatomically realistic human geometry and by verifying the numerical solution versus in vitro measurements.

Methods

The overall approach was to build a subject-specific multiphase computational fluid dynamics (CFD) model and to verify model results using a corresponding bench-top model. After verification, the models were used to quantitatively assess tracer removal by Neurapheresis therapy compared to lumbar drain. Fluorescein solution was used as a surrogate tracer and modeled as a bulk fluid phase within the CSF (28-31) to track clearance of blood components, specifically hemoglobin derivatives.

Model geometry

A high-resolution T2-weighted magnetic resonance imaging (MRI) sequence was used to acquire a subject-specific geometry of the CSF system of a 23-year-old healthy female subject (**Fig. 1a**). This model contained two main regions: 1) the spinal SAS and 2) the intracranial CSF space. The MRI protocol and image reconstruction method for the spinal SAS were previously described by Sass et al. (32). In brief, the spine model combined the high-resolution MR imaging with anatomic measurements and cadaveric studies in the literature and included 31 pairs of anatomically realistic spinal cord nerve roots, the filum terminale and the thecal sac (**Fig. 1b**).

A detailed intracranial CSF space geometry obtained with high-resolution MRI was added to the spinal SAS. The CSF space schematic in this region is shown in **Fig. 1c**. The intracranial CSF was manually segmented using ITK-SNAP (Version 3.4.0, University of Pennsylvania, U.S.A.), exported in .STL (Stereolithography) format, and imported into Blender (Amsterdam, Netherlands, Version 2.79). The model geometry was simplified within Blender to include the following key intracranial CSF spaces: a)

lateral ventricles and foramen of Monro (left and right), b) third ventricle and aqueduct of Sylvius, c) fourth ventricle and foramen of Luschka (lateral apertures), d) cisterna magna, e) pre-pontine and pontine cisterns, f) trigeminal cistern, g) quadrigeminal cistern, h) Sylvian cisterns (left and right), and i) cortical SAS (**Fig. 1c1**). The complex geometry of the cortical surface and the ventricular CSF system was smoothed and simplified such that the total cranial CSF volume remained equivalent to that of the original segmentation. The cortical SAS was divided at the midline to represent the falx cerebri and superior sagittal sinus. The posterior-superior aspect of the cerebellar cistern was terminated by a barrier representing the tentorium cerebelli. The cortical SAS was considered to cover the entire cortical surface with a uniform thickness of ~2.78 mm. To represent CSF production from the choroid plexus, CSF production ports with diameters of 5 mm were added to the superior aspect of the lateral ventricles (**Fig. 1c1**). A 5.5 mm diameter port was also added at the lumbar spine at the L3-L4 for catheter insertion. Each partitioned cistern was exported as a stereolithography (.STL) file and imported into Autodesk Netfabb (San Rafael, CA, Build 1608) to ascertain volume, surface area, and connectivity. The superior and inferior aspects of the model incorporated 22.5 mm diameter cylindrical passages with a length of 8 mm to accommodate oscillatory CSF pulsation to the system.

The dual-lumen Neurapheresis catheter geometry was identical with our previous publication (20). In brief, the catheter was inserted at L3-L4 and located within the posterior SAS with the aspiration port at L2 and the return port at T2 vertebral level (**Fig. 2a**). Internal and external catheter diameters were 0.5 and 0.7 mm for the wall of the inner lumen, and 1.7 and 1.5 mm for the outer lumen. A series of 11 holes were located at the return port and 12 holes at the aspiration port (**Fig. 2a1 and 2a2**).

176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198

Computational fluid dynamic model

Computational mesh

An unstructured tetrahedral computational mesh was generated using ANSYS ICEM 19.2 (Canonsburg, PA). Details on the prism layer and Mesh parameters are included in **Table 1** and **Fig. 1c2**. The mesh was refined near the catheter aspiration and return ports, since at these regions the geometric dimensions of the holes were relatively small. The mesh included the internal geometry of the return and aspiration ports to ensure correct flow distribution from each hole. The final mesh covering the Neurapheresis catheter, cranial, and spinal SAS had 16.8 Million cells. To allow verification of numerical results, an identical geometry was used for the in vitro model (**Fig. 1b**).

199 **TABLE 1.** Mesh details

Parameter	Type
Cell type:	Tetrahedral
Face type:	Triangle
Prism layer:	4
Prism Height:	0.05 (mm)
Growth law:	Exponential
Growth factor:	1.2
Mesh cells:	16.8 M
Mesh faces:	26.4 M
Mesh nodes:	3.7 M
Min mesh size:	0.05 (mm)
Max mesh size:	1.0 (mm)

200 Time step: 0.1 (s), Cycle: 5th, Time: 100 (s)

201

202 *Boundary conditions*

203 Clearance of tracer after SAH with Neurapheresis therapy and lumbar drain was
 204 studied under the following boundary conditions (**Fig. 2a**). The model system was
 205 oriented at 30° to horizontal to mimic a typical patient position within a hospital bed. Fluid
 206 was aspirated and returned under Neurapheresis therapy at 2.0 and 1.8 mL/min. The 0.2
 207 mL/min difference between return and aspiration matched the drain rate applied under
 208 lumbar drain (see details below). Constant CSF production from the choroid plexus within

the left and right ventricles was specified to be 0.1 mL/min (0.2 mL/min total) at the CSF production channel entrance. For the lumbar drain simulation, a drainage rate of 0.2 mL/min was specified, as this is a nominal value typically observed in the literature for that procedure (33, 34).

To represent CSF pulsation around the brain and spinal cord, an oscillatory velocity inlet boundary condition was defined at the model caudal opening using a User Defined Function. The exact waveform was derived from the C2-C3 CSF flow rate waveform (**Fig. 2b**) obtained from phase-contrast MR imaging of the healthy 23-year-old female subject (35). The angular frequency of the waveform was $\omega = 6.98 \text{ s}^{-1}$. A zero-pressure outlet boundary condition was defined at the cranial opening. No-slip boundary conditions were imposed at the model walls (dural, pial and intraventricular spaces) with the walls modeled as stationary. CSF was modeled as incompressible with a density of 998.3 kg/m^3 and viscosity of $0.89 \text{ mPa}\cdot\text{s}$. Tracer density and viscosity was assumed to be identical to CSF

Flow model

The pulsatile CSF flow field was computed using ANSYS Fluent 19.2 (Canonsburg, PA) by solving the continuity and Navier–Stokes equations

$$\nabla \cdot (\rho \mathbf{\bar{u}}) = 0 \quad (1)$$

$$\rho \frac{\partial \mathbf{\bar{u}}}{\partial t} + \rho \mathbf{\bar{u}} \cdot \nabla \mathbf{\bar{u}} = -\nabla p + \mu \nabla^2 \mathbf{\bar{u}} + \rho \mathbf{\bar{g}} \quad (2)$$

Where ρ is fluid density, μ is fluid viscosity, $\mathbf{\bar{g}}$ is acceleration due to gravity, $\mathbf{\bar{u}}$ is the velocity vector, and p is the pressure field.

231

232 *Multiphase model*

233 The 3D CFD computations used the ANSYS multi-phase fluid model to track the
 234 dispersion of a tracer within the CSF, with tracer volume fraction given by

$$235 \quad \frac{\partial}{\partial t}(\alpha_k \rho_k) + \nabla \cdot (\alpha_k \rho_k \vec{u}_m) - \nabla \cdot (\alpha_k \rho_k \vec{u}_{dr,k}) = 0 \quad (3)$$

236 where q is the bulk fluid phase, ρ_k and α_k are the phase density and volume fraction of

237 phase k , $\vec{u}_m = \frac{\sum_k \alpha_k \rho_k \vec{u}_k}{\rho_m}$ is the mass-averaged velocity, ρ_m is the mixture density, and

238 $\vec{u}_{dr,k}$ is the drift velocity for phase k , with phase $k=1$ being the CSF and $k=2$ for the tracer.

239 We assumed the relative velocity (slip velocity) between phase k and the bulk fluid to be
 240 zero. Thus, the drift velocity was considered to be zero.

241 Based on clinical SAH observations and previous research, we assumed a
 242 baseline tracer concentration of 10% ($\alpha_2=0.1$) throughout the model domain. Tangen et
 243 al. (36) showed that blood debris is evenly dispersed throughout the spinal SAS within
 244 the first hour post-SAH. For the present study, we expected at least 1-hour of time to
 245 have passed before a lumbar drain or Neurapheresis therapy system could be applied
 246 post-SAH. The lumbar puncture is a common clinical emergency procedure used to aid
 247 in SAH diagnosis (37). Medical doctors have observed the CSF samples from these SAH
 248 patients to be colored with a light pink shade (xanthochromia) (38), indicating that blood
 249 has spread throughout the CSF system down to the lumbar spine, justifying the evenly-
 250 mixed tracer concentration used in this model as a reasonable approximation. Steady-
 251 streaming velocities were determined based on the average of 10 CSF flow cycles with

transient effects eliminated by removal of the first flow cycle. Similar to Kuttler et al.(39), the fixed velocity field (“frozen flow field”) was used to solve the volume fraction equation for spatial-temporal tracer concentration. The axial distribution of tracer concentration, $\alpha(z)$, for 3 mm thick slices along the z-axis was computed by:

$$\alpha(z) = \frac{\sum_{slice} |\alpha_k(z)| V(z)}{\sum_{slice} V(z)} \quad (4)$$

Where V is the cell volume and summations were computed for all cells within each 3 mm thick cross-section. Spatial-temporal distribution of tracer concentration was plotted over 24-hours for Neurapheresis therapy and lumbar drain.

To determine concentration profiles over 24-hours after SAH, we determined the solute transport due to the steady-streaming CSF velocity field. Molecular diffusion of large molecules within the CSF (MW ~ 150 kDa) is much smaller than steady-streaming and oscillatory CSF velocities (39). However, shear and mixing across the cross section has the potential to greatly increase the effective diffusivity in the spinal SAS (40). Tangen et al.(36) found that molecular diffusion had a negligible impact on tracer spread within an idealized geometry representing the spinal and cranial SAS. However, the model included nerve roots, the simplified geometry likely reduced secondary mixing, which could increase the effect of dispersion. Kurtcuoglu et al.(41) also neglected diffusion in their model. To make the computational effort reasonable, molecular diffusion of the tracer was not included in the current study. However, as described in the following paragraphs, the potential impact of neglecting diffusion was estimated.

To help understand the relative importance of diffusive versus advective mass transport, the Sherwood number (Sh) was calculated. $Sh = \frac{h}{\mathbf{D}/L}$ provides the ratio of convective mass transport, h , to the effective diffusive mass transport, $\mathbf{D}/L$, where L is a characteristic length and $\mathbf{D}$ is the effective diffusivity including shear-augmented dispersion. h was computed based on the mean cross-sectional velocity at peak systolic ($h=0.26$ m/s and 2.4 m/s for cortical and spinal SAS, respectively). L was assumed to be the minimum gap width between the shells in the cortical SAS (~ 2 mm) and mean of the hydraulic diameter for the spinal SAS (5.87 mm).

To see if the tracer is a good similitude for hemoglobin clearance, $\mathbf{D}$ was calculated for both tracer and hemoglobin using an order-of-magnitude model by Sharp, et al. (40):

$$\mathbf{D} = (1 + R_{max})D \quad (5)$$

$$R_{max} = P^2 Sc / \alpha^2 \quad (6)$$

$$\alpha^2 = \beta^2 / Sc \quad (7)$$

$$\beta^2 = (L/2)^2 \omega / D \quad (8)$$

Where R_{max} is the maximum enhancements with optimal mixing, P is the characteristic non-dimensional pressure gradient ($P \sim 152.6$ (40)), α is Womersley number and β is oscillatory Peclet numbers. Schmidt number ($Sc = \frac{\nu}{D}$) was described as the ratio of momentum diffusivity of water at room temperature ($\nu = 0.89 \text{ E-06 m}^2/\text{s}$), to molecular diffusion coefficient (D). The molecular diffusivity of the fluorescein tracer is $D=4.25 \text{ E-10 m}^2/\text{s}$ (42, 43) and hemoglobin is $D=10.2 \text{ E-11 m}^2/\text{s}$ for (44).

293

294 *Solver settings*

295 Simulations were carried out using the PISO Scheme (pressure-implicit with splitting of
296 operators) to solve the flow equations with second-order upwind for momentum
297 discretization, PRESTO! (PREssure STaggering Options) for pressure discretization, and
298 first-order upwind for volume fraction discretization. Default values were used for under
299 relaxation factors. The implicit formulation was used for volume fraction parameters and
300 a dispersed model was used for phase interface modeling. The convergence criteria for
301 velocity, continuity, momentum, and phase volume fraction were set to 1E-06 with time
302 step = 0.1 s and maximum of 100 iterations per time-step. Total simulation time was 14
303 days to compute 24-hours of real-world time in parallel mode with 126 GB RAM and 38
304 processors. Time required to solve the fixed flow field (11 flow cycles) was 36 hours.

305 *Numerical sensitivity studies*

306 Axial distribution of average tracer concentration at one hour was verified by
307 numerical sensitivity studies for time-step size and mesh resolution. Results were
308 computed for a “coarse”, “medium”, and “fine” mesh with wall prism layers. For the
309 medium mesh, time-step sensitivity was then checked with time-step resolution given by
310 fractions of the cardiac cycle, $T = 0.9$ (s), for $T/18$, $T/9$, $T/5$. Based on these results, a
311 “Medium” mesh with time step = $T/9$ was carried forward for computation of final results.

312

313 *In vitro experimental model*

314 To help verify the numerical model results, an in vitro CSF model was constructed
315 with a fluid domain geometry identical to the numerical model. For the in vitro model, the

fluid domain was encased in a 2 mm thick transparent shell. The shell was divided into cranial (**Fig. 1b**), upper thoracic (**Fig. 1b1**), and lower spine (**Fig. 1b2**) pieces not exceeding the maximum build size of the 3D printer. The final digital geometry was submitted for STL 3D printing with a layer and in-plane resolution of 127 μm and 500 μm , respectively, for the cranial volume and 127 μm and 250 μm in the spinal column. The caudal end of the model was connected to a custom-built oscillatory flow pump imparting an identical CSF waveform utilized for the numerical simulation (**Fig. 2b**). The dual-lumen Neurapheresis catheter was inserted through an access port such that aspiration and return flow occurred at L2 and T2, locations that were congruent with the numerical model (**Fig. 2a**).

To mimic SAH blood distribution within the CSF, an aqueous solution of fluorescein sodium (25 mg / 1000 mL) was used to fill the entire model representing a uniform distribution of blood. A uniform distribution was assumed because previous research from Tangen et al (36) showed that blood debris is evenly dispersed throughout the spinal SAS within the first hour post-SAH. Usage of fluorescein as a surrogate tracer for blood is in agreement with previous studies that sought to track blood components in SAH, specifically hemoglobin derivatives (28-31). Experiments were conducted with deionized water, since the transport of SAH products is thought to be passive, i.e., the effects of chemical reactions are negligible (36). Fluorescein also does not mimic hydrodynamic effects on finite-size particles, such as the lift exerted on red cells near a boundary.

A continuous flow syringe pump (KD Scientific Legato 270, Holliston, MA) was used to aspirate fluid via the Neurapheresis catheter at 2.0 (mL min^{-1}). This same pump was also configured in parallel to return fresh deionized water at a rate of 2.0 mL/min.

This clean return flow was split and 0.2 mL/min was diverted by a second continuous flow syringe pump for CSF production originating from the ventricles. Thus a net flow of 1.8 mL/min was delivered to the return port of the Neurapheresis catheter. Another syringe pump was used to generate the subject-specific CSF flow wave from (**Fig. 2c**). Pump flow rates were verified by a graduated cylinder and stopwatch before each experiment. Identical to the numerical model, all experiments were conducted with the model at 30 degrees (head up) from horizontal .

The following digital image subtraction technique was applied to quantify spatial-temporal tracer concentration. The entire system was enclosed to block ambient light sources. The model was surrounded within the enclosure by blue wavelength (450 (nm)) light emitting diodes triggered to a camera flash. For model calibration, a baseline image was obtained without any tracer introduced to the model. To establish baseline decay of the fluorescein tracer, time-lapse imaging was obtained at 5-minute intervals over a total of 24-hours with the tracer solution at a known concentration 15 μ M. To eliminate aliasing artifacts due to CSF oscillations, images were collected with a trigger set to the cardiac systole. An identical series of images was then collected for the same experiment under Neurapheresis therapy and also with lumbar drain.

Spatial-temporal distribution of tracer concentration for each case was computed as $\alpha = \frac{I_{\text{exp}} - I_0}{I_b - I_0}$, where I_{exp} is the signal intensity for each case, I_0 is the background image intensity at zero concentration and I_b is the baseline decay. To account for lens distortion, the distance and orientation of the camera to the model was measured and used to correct axial pixel position for comparison to CFD results. Similar to the CFD

simulations, spatial distribution of tracer concentration was averaged for 3 mm thick slices along the model (z-direction).

12-bit images were collected with 12 MP resolution using a digital camera (Sony alpha a7s ii) with a 50 mm focal length prime lens with f/10 aperture (Sony E 50 mm f/1.8 OSS). Imaging settings were 2000 ISO, white balance 5500 Kelvin, and 1/100 s shutter speed. A 525 nm bandpass filter (Midwest optical systems BP525-49) was used in front of the lens to improve image signal-to-noise ratio.

Geometric and Hydrodynamic Quantification

Based on the 3D reconstruction and meshing, the following geometric and hydrodynamic parameters were calculated along the spine at 1 mm intervals using our previously described methods (45). Reynolds number based on hydraulic diameter was

calculated as $Re = \frac{|Q_{\max}| D_H}{\nu A_{cs}}$, where $|Q_{\max}|$ is the absolute value of the peak flow rate from

the flow rate waveform at each cross section, D_H is hydraulic diameter, A_{cs} is the cross-sectional area and ν is kinematic viscosity. Womersley number was quantified as

$\alpha = \frac{D_H}{2} \sqrt{\omega / \nu}$ where $\omega = 2\pi / T$ is angular velocity and T is the cycle period. Mean cross

sectional velocity at peak systolic and diastolic flow, was computed as $\frac{Q_{peak}}{A_{cs}}$, with Q_{peak}

defined as the maximum flow rate at peak systole and diastole at each slice.

Quantification of steady-streaming CSF flow

To quantify steady-streaming, the cyclic mean velocity in the z-direction, U_{z-mean} , was computed for each node in the computational mesh as a summation of z-velocity on each node during one cycle similar to our previous publication (24). U_{z-mean} was visualized at a mid-sagittal slice for Neurapheresis therapy and lumbar drain. A positive value for U_{z-mean} indicates steady-streaming in the rostral direction. U_{z-mean} was used in Sh number calculations as a convective mass transfer term, h , since the dominant velocity field in the simulation was assumed to be equal to U_{z-mean} . The axial distribution of steady-streaming, $U_{ss}(z)$, was estimated by computing the cross-sectional average of U_{z-mean} magnitude:

$$U_{ss}(z) = \frac{\sum_{cell} |U_{z-mean}(z)| V(z)}{\sum_{cell} V(z)} \quad (9)$$

where the summations are over all cells in the cross section at a given z location. $U_{ss}(z)$ was calculated for z-slices at 1 mm intervals along the spine. To further quantify the magnitude of steady-streaming flow, a non-dimensional fraction of the specified flow rate amplitude was defined as:

$$Q_{ss(z)} = \frac{U_{ss}(z) A_{cs}}{2Q_{peak}} \quad (10)$$

Verification of numerical results

A detailed comparison of numerical and in vitro results was performed by the following correlation analysis similar to that previously conducted by our group (46). In vitro experiments were conducted using fluorescein as a tracer (as described above)

401 under Neurapheresis therapy and lumbar drain. In vitro and CFD spatial-temporal tracer
402 concentration results were compared by linear regression and Bland-Altman plot analysis
403 with 95% confidence interval calculations.

404

Results

Overall, numerical and in vitro results showed agreement in terms of spatial-temporal concentration of tracer over the 24-hour simulation period. Neurapheresis therapy was found to clear tracer from the CSF more rapidly than lumbar drain with most of the clearance occurring within the thoracic SAS after 1-hour of treatment.

Geometric and hydrodynamic parameters

A summary of volumetric parameters for the model is included in **Table 2**. Total length of the SAS (cranial and spinal) was 75.6 cm. Spinal SAS volume was 100.3 mL and intracranial CSF volume was 221.6 mL. Hydraulic diameter and Womersley number had an average value of 6.2 mm and 9.8 within SAS (**Figure 3a**). Local maxima for hydraulic diameter and Womersley number were located at the foramen magnum. Mean CSF velocity had the greatest values in the lumbar spine at -4.7 and 2.8 cm/s for the peak systole and diastole, respectively. Minimum of the mean velocity occurred in the cranial SAS (**Figure 3b**). Mean cross-sectional perimeter and area were 28.3 cm and 4.2 cm², respectively. As expected, maximum area and perimeter was located at the cranium (**Figure 3c-d**). A notable increase in area and perimeter was present at ~5 cm cranial to the foramen magnum where the lateral ventricles are located. Maximum Reynolds number was 461 and was located at the caudal end of lumbar spine where the in vitro model tubing entered the system (required for the in vitro model flow pump connection) (**Figure 3e**).

428 **TABLE 2.** CSF space geometric parameters.

Parameter	Volume (mL)
Spinal cord	19.6
Nerve roots	6.0
Dura	125.9
Total Spinal CSF	100.3
Cortical SAS	153.6
Ventricular system	19.7
Cerebellar SAS	21.8
Basal cisterns	26.5
Total Intracranial CSF	221.6
<i>Total CSF</i>	<i>321.9</i>

429 Total Spinal CSF = Dura – (Nerve roots + Spinal cord)

430 Total Intracranial CSF = Cortical SAS + Ventricular system + Cerebellar SAS + Basal cisterns

431

432

433 ***Numerical quantification of steady-streaming CSF velocities and dimensionless***
 434 ***parameters***

435 Neurapheresis therapy was found to have a larger impact on U_{z-mean} and $U_{ss}(z)$ in
 436 comparison to lumbar drain. Overall, Neurapheresis therapy resulted in greater steady-
 437 streaming velocity magnitude within the region between the return and aspiration ports
 438 (**Fig. 4**). The sagittal U_{z-mean} velocity profile indicated a large region of caudally directed

steady-streaming on the posterior side of the middle thoracic SAS during Neurapheresis therapy. U_{z-mean} within this region decreased with lumbar drain. However, steady-streaming remained similar between the two therapies on the anterior side of the cervical SAS. The coronal U_{z-mean} velocity profile was of a smaller magnitude and similar in both Neurapheresis therapy and lumbar drain (**Fig. 4a**). U_{z-mean} indicated a cranially directed steady-streaming in the left frontal cranial SAS and caudally directed steady-streaming elsewhere. Steady-streaming in the cranial SAS was ~50X smaller than in the spinal SAS for both Neurapheresis therapy and lumbar drain (**Fig. 4b**). The average value of U_{ss} between the aspiration and return ports was 60% greater with Neurapheresis therapy (0.37 mm s⁻¹ versus 0.23 mm 1/s for lumbar drain) (**Fig. 4c**). Q_{ss} showed a nearly identical trend as U_{ss} . The average value for Q_{ss} between the aspiration and return ports was 0.040 and 0.025 for Neurapheresis therapy and lumbar drain, respectively (**Fig. 4d**).

The square of the Womersley number and oscillatory Peclet numbers were calculated to estimate the potential enhancement of dispersion by shear. For both tracer and hemoglobin α^2 is 7.84 in the cortical SAS and 67.55 in the spinal SAS. The Womersley number is in the unsteady flow regime in the spinal SAS, but only marginally in the cortical SAS.

β^2 for tracer and hemoglobin is 1.64 E+04 6.84 E+04 in the cortical SAS and 1.41 E+05 and 5.89 E+05 in spinal SAS. The large Peclet numbers indicate that dispersion is unsteady, thus secondary mixing across the cross section can increase axial dispersion.

R_{max} for tracer and hemoglobin is 6.21 E+06 and 2.59 E+07 in the cortical SAS and 7.2 E+05 and 3.0 E+06 in the spinal SAS. Since R_{max} is large compared to unity, the

effective diffusivity is independent of molecular diffusivity. Therefore D is $0.0026 \text{ m}^2/\text{s}$ in the cortical SAS and $3.0677 \text{ E-}04 \text{ m}^2/\text{s}$ in the spinal SAS. Sh number for the tracer and hemoglobin was calculated to be $7.5 \text{ E-}06$ at the cortical SAS and $9.6 \text{ E-}03$ at the spinal SAS, respectively.

Comparison of tracer concentration

Baseline tracer concentration was set to 10% throughout the model. After 24-hours, tracer concentration was reduced to 4.9% under Neurapheresis therapy compared to 6.5% under lumbar drain. Tracer clearance in the thoracic region occurred more rapidly after one hour under Neurapheresis therapy compared to lumbar drain (**Fig. 5a1** and **5b1**, Thoracic). There was little difference in the intracranial cross-sectional average tracer concentration for Neurapheresis therapy versus lumbar drain (6.6% in both cases) (**Fig. 5a1** and **5b1**, Head). Cross-sectional average tracer concentration decreased to $\sim 1.5\%$ in the spinal SAS after one hour (**Fig. 5a2**) compared to 6.5% with lumbar drain after 24-hour (**Fig. 5b2**). Spatial-temporal distribution of tracer clearance under Neurapheresis therapy showed that maximum clearance occurred caudal to the return port ($z = -15 \text{ cm}$).

The highest deviations between the in vitro and CFD occurred in the cranial region (**Fig. 5a3**). The minimum tracer concentration in the cranial region occurred near the ventricles where the CSF production channels are located ($\sim z=10 \text{ cm}$). Comparison of spatial-temporal tracer clearance trends with lumbar drain showed nearly identical results for both CFD and in vitro while the clearance rate decreased gradually in caudal direction (**Fig. 5b3**).

2D tracer concentration profiles were relatively uniform around the spinal cord circumference (X and Y directions) under both Neurapheresis therapy (**Fig. 6a**) and lumbar drain (**Fig. 6b**). In contrast, tracer concentration was non-uniform around the brain with local tracer concentration reduction near the cerebellum due to CSF production from the ventricles via the foramen Luschka and Magendie.

Quantitative comparison of in vitro and numerical simulations

Overall, the distributions and clearance rates of tracer concentration in Neurapheresis therapy and lumbar drain match the bench-top patterns. Numerical simulations predicted slightly faster clearance rates under Neurapheresis therapy and lumbar drain than in vitro (**Fig. 5**).

Differences between spatial-temporal cross-sectional average tracer concentration over 24-hours obtained from in vitro and CFD were quantified using Bland–Altman plots (**Fig. 7**). A relatively strong linear correlation was observed between the numerical and in vitro results for Neurapheresis therapy (**Fig. 7a1**, $R^2 = 0.89$, slope = 1.01). Linear correlation for the lumbar drain case was moderate (**Fig. 7b1**, $R^2 = 0.65$, slope = 1.2). The second set of Bland–Altman plots (**Fig. 7a2** and **7b2**) showed that a greater discrepancy between in vitro and CFD results tended to occur for z-positions closer to the cranium. The 95% confidence intervals for Neurapheresis therapy and lumbar drain were +2.13 to -1.93% and +2.29 to -2.69%, respectively (**Fig. 7a2** and **7b2**).

Discussion

The CFD and in vitro model provided a systematic comparison of lumbar drain to Neurapheresis therapy after SAH. These models allow detailed comparison of results without the confounding impact of many variables that would be difficult to control for in vivo animal models or SAH patients. Computer simulations provided the theoretical basis to interpret bench top in vitro results by better elucidating the complex tracer clearance patterns in pulsatile CSF after SAH.

In vitro verification of numerical results

Studies show that wide variability exists in CFD modeling techniques and the choice of numerical solvers and settings are complex and can yield disparate results for biofluids simulations (47). Thus, in vitro models play a critical role to help verify numerical results. Unfortunately, at present there is no known method to map exact spatial-temporal blood concentration within the CSF over time for SAH patients. Thus, a true model validation against in vivo measurements is not possible. The model results are presented as a prediction for how blood can potentially be removed from the CSF.

Comparison of spatial-temporal cross-sectional average tracer concentration profiles revealed similar clearance trends for both CFD and in vitro under Neurapheresis therapy and lumbar drain conditions (**Fig 5**). A strong linear correlation was found between CFD and in vitro results under Neurapheresis therapy ($R^2=0.89$, **Fig 7a1**), and a moderate linear correlation for lumbar drain ($R^2 = 0.65$, **Fig 7b1**). Lumbar drain correlation was lower likely due to the lower degree of tracer changes that were present in that experiment. It was noted that linear correlation of results was stronger within the

central region of the models. We expect that results had improved agreement within the central region of the model because our optical imaging field of view was most accurately aligned to CFD results within that region of the model. Near the model ends, the camera viewing angle was not orthogonal to the model domain and therefore did not provide information in the exact axial z-orientation as CFD results. Even with these in vitro imaging limitations, CFD results showed 95% of the CFD tracer concentration results were within ~2% of the in vitro findings with a mean difference of ~0.1% in both cases (**Fig 7a2 and b2**). In combination, these results help verify the numerical modeling approach using a frozen flow field that excluded mass diffusion. While these results agree, they cannot be assumed to correctly represent in vivo as many model assumptions were made that may not exactly represent in vivo CSF mass transport (see limitations). These model predictions should be tested against in vivo measurements in animals and/or humans.

Our model results are difficult to directly compare with previous research as no study has been conducted previously with an anatomically realistic model and with Neurapheresis therapy applied with an exact catheter geometry. However, Tangen et al (36) used an anatomically idealized bench-top CSF model and corresponding CFD analysis to study CSF blood clearance following SAH under various body orientations and lumbar drain rates with an intraventricular catheter inserted for 3 hours. They found the fastest blood clearance was achieved in the vertical body position and that an increase in lumbar drainage flow rate accelerated blood clearance. Their results, using a lumbar drain and intraventricular catheter, showed that after 60 minutes of filtration, contamination concentration was 3.5% at the T6 vertebral level. After 60 minutes, tracer

clearance was 1.5 % at T6 in our numerical model using Neurapheresis therapy (**Fig 5a1**). This difference is likely due to the 2X higher filtration rate applied in our study 2.0 mL/min versus 1.0 mL/min by Tangen et al. Also, for the lumbar drain case with 0.2 mL/min drainage rate, 12% clearance was observed in Tangen et al (36) versus 10% clearance in our simulation. Since drainage rate for lumbar drain is equal on both studies, the clearance rates are similar.

Comparison of Neurapheresis therapy and lumbar drain

After 24 hours, results from Neurapheresis therapy showed that 4.9% of tracer remained in the model (**Fig 6a**) while 6.5% tracer concentration remained after lumbar drainage (**Fig 6b**). Cranial tracer clearance was nearly identical in both the lumbar drain and Neurapheresis therapy (**Fig 5a1** and **5b1**). The mechanistic reason for increased tracer clearance under Neurapheresis therapy is that it applies a CSF flow loop that returns filtered CSF back to the upper thoracic spine. The CSF flow loop increases steady-streaming velocities within the flow loop region (**Fig. 4**), which allows more rapid removal of the tracer. While the clinical impact of greater blood clearance on SAH outcomes has not been proven, researchers have shown the potential that more quickly reducing the levels of blood and inflammatory cytokines in the CSF post SAH could improve outcomes (48, 49)

The Neurapheresis therapy flow rate applied in our study was 2.0 (mL/min) with a 1.8 mL/min return flow rate. A flow rate of 2.0 mL/min is not possible to apply using a lumbar drain because it would remove CSF more rapidly than it is being produced at the choroid plexus (~500 mL/day) (50). To help compare Neurapheresis and lumbar drain

tracer clearance efficiency, we compared tracer clearance under a lumbar drain and Neurapheresis waste rate both set to 0.2 mL/min (288 mL in 24 hours). To the best of our knowledge, this flow rate represents an upper bound for what is possible to withdraw under lumbar drain. In clinical practice, the drainage rate settings for lumbar drains may be lower.

Importance of frozen field approach in the numerical model

Transient simulations of oscillating fluids are computationally intensive, in particular when conducted over long time periods with small time-step size. For example, in the present case representing CSF oscillations, computation of a single CSF flow cycle requires ~3.6 hours using 38 processors (Intel(R) Xeon(R) Gold 6148 CPU @ 2.40GHz) and 126 (GB) Memory. Simultaneously solving the passive transport equation requires additional time. Neurapheresis therapy is conducted over a period of more than 24-hours. As such, we applied a two-part CFD method that neglected diffusion to obtain a computationally tractable solution over the 24-hour timeframe. First, a transient Navier-Stokes solution of 11 flow cycles was performed to obtain the steady-streaming velocity field. Second, the velocity field was applied as a “frozen flow field” as described by Kuttler et al.(39). The frozen field approach is valid for periodic flow when advection is the main mode of mass transport. The Sh numbers computed in our study, by using the effective diffusivity of the tracer, were 7.56 E-06 and 9.6 E-03 for the cortical and spinal SAS, respectively. It should be noted that the low Sherwood number based on R_{max} does not necessarily convey that shear-augmented diffusion is important, in particular for the present case in which substantial mixing can be produced by the complex spinal cord

nerve root geometry. Further study is needed to compare the effect of diffusion to steady-streaming based advection.

In this study, we did not include the potential impact of microscopic anatomy within the domain such as arachnoid trabeculae or blood vessels, nor hydrodynamic effects on finite-size particles (red blood cells, in particular). Other numerical studies have investigated the potential impact of microscopic structures (40) within the CSF and found they can have varying degrees of impact on solute transport (51-53) and pressure gradients (54). Thus, our numerical and in vitro predictions should be confirmed with in vivo experiments. Albeit, these experiments may not be possible at present as we do not have a non-invasive in vivo imaging modality that can quantify blood concentration throughout the CSF system over 24-hours.

Limitations

In this study, blood dispersion was modeled by fluorescein tracer mixed in a single continuum CSF phase at room temperature. Physiologically, blood cells and debris create a suspension when mixed into CSF. The biochemistry of blood coagulation within the CSF was not reproduced. Additionally, once exposed to the SAS environment, blood cells can rupture releasing oxyhemoglobin which is further enzymatically converted to bilirubin (55, 56). While the electrolytes and enzymatic interactions between blood components and CSF have an impact, our fluid mechanical study did not take into account pharmacokinetics of blood proteins, blood cell lysis, and blood cell component metabolism. Accounting for red blood cell byproducts and reaction kinetics could provide a more realistic scenario for testing biochemical effects of SAH. However, the effective

diffusivity is independent of molecular diffusivity since $R_{\max}$ is large compared to unity. Therefore, the chosen tracer provides good similitude for blood. The in vitro experiments were performed at 19 °C. We did not create a thermostatic environment due to size limitations, because the density ratio between CSF and fluorescein tracer is not different whether the experiment is conducted at 19 °C or at body temperature of 37 °C.

In the comparison between simulation and experiments, the highest deviations occurred in the cranial SAS. It is likely these differences were larger in the cranial SAS due to the 2D imaging technique that used a picture obtained for a single angle relative to the model. Whereas, the CFD concentrations were precisely averaged across each 3 mm thick slice. Future work could potentially improve agreement of in vitro and numerical results by utilizing tomographic projection imaging (57) of the in vitro model or quantitative contrast enhanced MRI techniques (58).

The numerical simulation in this study were based on MRI measurements for a single subject-specific CSF system geometry and CSF flow waveform. These parameters should be investigated in a larger cohort to determine the potential impact of age, sex, and disease states on CSF solute transport. Also, for future research, we may need to investigate the effect of filtration for a longer periods of 48, 72 or 120 hours for different neurological conditions (59).

Our modeling approach did not include flow oscillations within the ventricles (60, 61) or a respiratory component of CSF pulsations (62-64) because the MRI scanning time did not allow measurement of these parameters in addition to the other parameters used to formulate the model. Additionally, the presented model used a rigid material in which boundary motion of the dura was not prescribed (24). This model also did not account for

permeability of the CNS tissue or dura matter (65). We chose a rigid model without permeability to allow verification of numerical results in a precisely known domain. Future studies should investigate the relevance of tissue permeability and motion.

No attempt was made in this study to optimize catheter design or positioning for Neurapheresis therapy. The effect of Neurapheresis therapy on CSF steady-streaming velocities in the spinal SAS were investigated in our previous study (20). The present study extended the previous model by including a complete CSF system, integration of a two-phase model, and developing a method for in vitro verification of results.

Conclusions

A subject-specific CFD model of the CSF system was formulated and applied to compare the impact of Neurapheresis therapy on tracer removal from CSF compared to lumbar drain over a 24-hour period. Results were verified with an in vitro model built identical to the CFD model. The numerical modeling approach using a frozen flow field to represent solute transport resulted in similar solute transport dynamics as that seen in vitro. Neurapheresis therapy was found to significantly increase tracer clearance compared to a lumbar drain. The overall tracer concentration after a 24-hour period for Neurapheresis therapy was 4.9% compared to 6.5% with lumbar drain. This effect was maximized within the region between the return and the aspiration ports in Neurapheresis therapy.

667 **List of Abbreviations**

P	Density (Kg m^{-3})
M	Dynamic viscosity (Pa s)
N	Kinematic viscosity ($\text{m}^2 \text{s}^{-1}$)
A	Volume fraction
A	Area
D	Diffusion coefficient
H	Convective mass transport
I	Signal intensity
L	Characteristic length
Q	Flow rate
U	Velocity
V	Cell volume
D_H	Hydraulic diameter
Re	Reynolds number
Sc	Schmidt number
Sh	Sherwood number
CFD	Computational fluid dynamics
CNS	Central nervous system
CSF	Cerebrospinal fluid
MRI	Magnetic resonance imaging
SAH	Subarachnoid hemorrhage
SAS	Subarachnoid spaces

668

Declarations

Ethics approval and consent to participate

In this study, all the MRI data collection development was approved by the local institutional review board in Amiens, France and satisfied all local and international regulations for human subject research. All data was de-identified before transferring to the University of Idaho for further analysis.

Consent for publication

All authors have approved the manuscript submission. The content of this manuscript has not been published or submitted for publication elsewhere.

Availability of data and material

The data that support the findings of this study are available from the corresponding author, [BAM], upon reasonable request.

Competing interests

BAM has received research funding from Biogen Inc., KBR Wyle, Alcyone Lifesciences Inc., Minnetronix Inc., and Voyager Therapeutics.

Funding

This work was supported by Minnetronix Corp., an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of health (NIH) under Grant #P20GM1033408 and #4U54GM104944-04TBD,

692 The National Institute of Mental Health Grant #1R44MH112210-01A1, National Institute
693 of Neurological Disorders and Stroke Grant# R01NS111283, and University of Idaho
694 Vandal Ideas Project.

695

696 ***Author contributions***

697 Study conception and design: BAM, MK

698 Acquisition of data: MK, LRS

699 Analysis and interpretation of data: MK, BAM, LRS

700 Drafting of manuscript: MK, BAM

701 Critical revision: BAM, MKS, AM, LZV, SPL

702

703 ***Acknowledgments***

704 None.

REFERENCES

1. Wright BL, Lai JT, Sinclair AJ. Cerebrospinal fluid and lumbar puncture: a practical review. *J Neurol.* 2012;259(8):1530-45.
2. Del Bigio MR. Ependymal cells: biology and pathology. *Acta Neuropathol.* 2010;119(1):55-73.
3. Sakka L, Coll G, Chazal J. Anatomy and physiology of cerebrospinal fluid. *Eur Ann Otorhinolaryngol Head Neck Dis.* 2011;128(6):309-16.
4. Brodbelt A, Stoodley M. CSF pathways: a review. *Br J Neurosurg.* 2007;21(5):510-20.
5. Spector R, Robert Snodgrass S, Johanson CE. A balanced view of the cerebrospinal fluid composition and functions: Focus on adult humans. *Exp Neurol.* 2015;273:57-68.
6. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. *Arch Neurol.* 2005;62(6):865-70.
7. Hatterer E, Touret M, Belin MF, Honnorat J, Nataf S. Cerebrospinal fluid dendritic cells infiltrate the brain parenchyma and target the cervical lymph nodes under neuroinflammatory conditions. *Plos One.* 2008;3(10):e3321.
8. Simon MJ, Iliff JJ. Regulation of cerebrospinal fluid (CSF) flow in neurodegenerative, neurovascular and neuroinflammatory disease. *Biochim Biophys Acta.* 2016;1862(3):442-51.
9. Hardemark HG, Persson L, Bolander HG, Hillered L, Olsson Y, Pahlman S. Neuron-Specific Enolase Is a Marker of Cerebral-Ischemia and Infarct Size in Rat Cerebrospinal-Fluid. *Stroke.* 1988;19(9):1140-4.
10. Zetterberg H, Smith DH, Blennow K. Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. *Nat Rev Neurol.* 2013;9(4):201-10.
11. Klimo P, Jr., Kestle JR, MacDonald JD, Schmidt RH. Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. *J Neurosurg.* 2004;100(2):215-24.
12. Macdonald RL. Pathophysiology and molecular genetics of vasospasm. *Cerebral Vasospasm.* 2001;77:7-11.
13. Weir B, Macdonald RL, Stoodley M. Etiology of cerebral vasospasm. *Acta Neurochir Suppl.* 1999;72:27-46.
14. Prim Capdevila J, Campillo Valero D, Coello Gomez F. [Hydrocephalus after subarachnoid hemorrhage]. *Neurologia.* 1990;5(2):41-4.
15. Hoekema D, Schmidt RH, Ross I. Lumbar drainage for subarachnoid hemorrhage: technical considerations and safety analysis. *Neurocrit Care.* 2007;7(1):3-9.
16. Inagawa T, Kamiya K, Matsuda Y. Effect of continuous cisternal drainage on cerebral vasospasm. *Acta Neurochir (Wien).* 1991;112(1-2):28-36.
17. Kawamoto S, Tsutsumi K, Yoshikawa G, Shinozaki MH, Yako K, Nagata K, et al. Effectiveness of the head-shaking method combined with cisternal irrigation with urokinase in preventing cerebral vasospasm after subarachnoid hemorrhage. *J Neurosurg.* 2004;100(2):236-43.

18. Nakagomi T, Takagi K, Narita K, Nagashima H, Tamura A. Cisternal washing therapy for the prevention of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. *Acta Neurochir Suppl.* 2001;77:161-5.
19. Sasaki T, Kodama N, Kawakami M, Sato M, Asari J, Sakurai Y, et al. Urokinase cisternal irrigation therapy for prevention of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage: a study of urokinase concentration and the fibrinolytic system. *Stroke.* 2000;31(6):1256-62.
20. Khani M, Sass L, McCabe A, Zitella Verbick L, Lad SP, Sharp MK, et al. Impact of Neurapheresis system on intrathecal cerebrospinal fluid dynamics: a computational fluid dynamics study. *J Biomech Eng.* 2019.
21. Blackburn SL, Swisher CB, Grande AW, Rubi A, Verbick LZ, McCabe A, et al. Novel Dual Lumen Catheter and Filtration Device for Removal of Subarachnoid hemorrhage: First Case Report. *Oper Neurosurg (Hagerstown).* 2018.
22. Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter (PILLAR) 2018 [Available from: <https://clinicaltrials.gov/ct2/show/NCT02872636?term=pillar&cond=Subarachnoid+Hemorrhage&rank=1>.
23. Blackburn SL, Grande AW, Swisher CB, Hauck EF, Jagadeesan B, Provencio JJ. Prospective Trial of Cerebrospinal Fluid Filtration After Aneurysmal Subarachnoid Hemorrhage via Lumbar Catheter (PILLAR). *Stroke.* 2019;50(9):2558-61.
24. Khani M, Sass L, Xing T, Sharp MK, Balédent O, Martin B. Anthropomorphic Model of Intrathecal Cerebrospinal Fluid Dynamics Within the Spinal Subarachnoid Space: Spinal Cord Nerve Roots Increase Steady-Streaming. *Journal of Biomechanical Engineering.* 2018.
25. Khani M, Lawrence BJ, Sass LR, Gibbs CP, Pluid JJ, Oshinski JN, et al. Characterization of intrathecal cerebrospinal fluid geometry and dynamics in cynomolgus monkeys (*macaca fascicularis*) by magnetic resonance imaging. *Plos One.* 2019;14(2):e0212239.
26. Smilnak GJ, Charalambous LT, Cutshaw D, Premji AM, Giamberardino CD, Ballard CG, et al. Novel Treatment of Cryptococcal Meningitis via Neurapheresis Therapy. *J Infect Dis.* 2018;218(7):1147-54.
27. Tangen K, Linninger A, Narasimhan NS. Clearance of subarachnoid hemorrhage from the central nervous system via lumbar drain - a bench-top and computational study. *Cerebrovascular Diseases.* 2016;41:202-.
28. Steuer H, Jaworski A, Stoll D, Schlosshauer B. In vitro model of the outer blood-retina barrier. *Brain Res Brain Res Protoc.* 2004;13(1):26-36.
29. Singh NP, Roberts DN. An inexpensive blue filter for fluorescein-assisted repair of cerebrospinal fluid rhinorrhea. *Laryngoscope.* 2014;124(5):1103-5.
30. Fu BMM, Shen S. Structural mechanisms of acute VEGF effect on microvessel permeability. *American Journal of Physiology-Heart and Circulatory Physiology.* 2003;284(6):H2124-H35.
31. Kozler P, Pokorny J. Altered blood-brain barrier permeability and its effect on the distribution of Evans blue and sodium fluorescein in the rat brain applied by intracarotid injection. *Physiol Res.* 2003;52(5):607-14.

32. Sass LR, Khani M, Natividad GC, Tubbs RS, Baledent O, Martin BA. A 3D subject-specific model of the spinal subarachnoid space with anatomically realistic ventral and dorsal spinal cord nerve rootlets. *Fluids Barriers CNS*. 2017;14(1):36.
33. Fedorow CA, Moon MC, Mutch WAC, Grocott HP. Lumbar Cerebrospinal Fluid Drainage for Thoracoabdominal Aortic Surgery: Rationale and Practical Considerations for Management. *Anesthesia and Analgesia*. 2010;111(1):46-58.
34. Weaver KD, Wiseman DB, Farber M, Ewend MG, Marston W, Keagy BA. Complications of lumbar drainage after thoracoabdominal aortic aneurysm repair. *Journal of Vascular Surgery*. 2001;34(4):623-7.
35. Khani M, Sass LR, Xing T, Keith Sharp M, Baledent O, Martin BA. Anthropomorphic Model of Intrathecal Cerebrospinal Fluid Dynamics Within the Spinal Subarachnoid Space: Spinal Cord Nerve Roots Increase Steady-Streaming. *J Biomech Eng*. 2018;140(8).
36. Tangen K, Narasimhan NS, Sierzega K, Preden T, Alaraj A, Linninger AA. Clearance of Subarachnoid Hemorrhage from the Cerebrospinal Fluid in Computational and In Vitro Models. *Ann Biomed Eng*. 2016;44(12):3478-94.
37. Gorchynski J, Oman J, Newton T. Interpretation of traumatic lumbar punctures in the setting of possible subarachnoid hemorrhage: who can be safely discharged? *Cal J Emerg Med*. 2007;8(1):3-7.
38. Perry JJ, Alyahya B, Sivilotti MLA, Bullard MJ, Emond M, Sutherland J, et al. Differentiation between traumatic tap and aneurysmal subarachnoid hemorrhage: prospective cohort study. *Bmj-Brit Med J*. 2015;350.
39. Kuttler A, Dimke T, Kern S, Helmlinger G, Stanski D, Finelli LA. Understanding pharmacokinetics using realistic computational models of fluid dynamics: biosimulation of drug distribution within the CSF space for intrathecal drugs. *Journal of Pharmacokinetics and Pharmacodynamics*. 2010;37(6):629-44.
40. Keith Sharp M, Carare RO, Martin BA. Dispersion in porous media in oscillatory flow between flat plates: applications to intrathecal, periarterial and paraarterial solute transport in the central nervous system. *Fluids and Barriers of the CNS*. 2019;16(1):13.
41. Kurtcuoglu V, Soellinger M, Summers P, Poulikakos D, Boesiger P. Mixing and modes of mass transfer in the third cerebral ventricle: a computational analysis. *J Biomech Eng*. 2007;129(5):695-702.
42. Casalini T, Salvalaglio M, Perale G, Masi M, Cavallotti C. Diffusion and Aggregation of Sodium Fluorescein in Aqueous Solutions. *Journal of Physical Chemistry B*. 2011;115(44):12896-904.
43. Culbertson CT, Jacobson SC, Michael Ramsey J. Diffusion coefficient measurements in microfluidic devices. *Talanta*. 2002;56(2):365-73.
44. Longeville S, Stingaciu LR. Hemoglobin diffusion and the dynamics of oxygen capture by red blood cells. *Sci Rep*. 2017;7(1):10448.
45. Khani M, Xing T, Gibbs C, Oshinski JN, Stewart GR, Zeller JR, et al. Nonuniform Moving Boundary Method for Computational Fluid Dynamics Simulation of Intrathecal Cerebrospinal Flow Distribution in a Cynomolgus Monkey. *J Biomech Eng*. 2017;139(8):081005.
46. Heidari Pahlavian S, Bunck AC, Thyagaraj S, Giese D, Loth F, Hedderich DM, et al. Accuracy of 4D Flow Measurement of Cerebrospinal Fluid Dynamics in the Cervical

- Spine: An In Vitro Verification Against Numerical Simulation. *Ann Biomed Eng.* 2016;44(11):3202-14.
47. Valen-Sendstad K, Bergersen AW, Shimogonya Y, Goubergrits L, Bruening J, Pallares J, et al. Real-World Variability in the Prediction of Intracranial Aneurysm Wall Shear Stress: The 2015 International Aneurysm CFD Challenge. *Cardiovasc Eng Technol.* 2018;9(4):544-64.
48. Maeda Y, Shirao S, Yoneda H, Ishihara H, Shinoyama M, Oka F, et al. Comparison of lumbar drainage and external ventricular drainage for clearance of subarachnoid clots after Guglielmi detachable coil embolization for aneurysmal subarachnoid hemorrhage. *Clinical Neurology and Neurosurgery.* 2013;115(7):965-70.
49. Kwon OY, Kim YJ, Kim YJ, Cho CS, Lee SK, Cho MK. The utility and benefits of external lumbar CSF drainage after endovascular coiling on aneurysmal subarachnoid hemorrhage. *Journal of Korean Neurosurgical Society.* 2008;43(6):281-7.
50. Hall JE, Guyton AC. Guyton and Hall textbook of medical physiology. 12th ed. Philadelphia, Pa.: Saunders/Elsevier; 2011. xix, 1091 p. p.
51. Tangen KM, Hsu Y, Zhu DC, Linninger AA. CNS wide simulation of flow resistance and drug transport due to spinal microanatomy. *J Biomech.* 2015;48(10):2144-54.
52. Stockman HW. Effect of anatomical fine structure on the flow of cerebrospinal fluid in the spinal subarachnoid space. *J Biomech Eng.* 2006;128(1):106-14.
53. Stockman HW. Effect of anatomical fine structure on the dispersion of solutes in the spinal subarachnoid space. *J Biomech Eng.* 2007;129(5):666-75.
54. Gupta S, Soellinger M, Boesiger P, Poulikakos D, Kurtcuoglu V. Three-dimensional computational modeling of subject-specific cerebrospinal fluid flow in the subarachnoid space. *J Biomech Eng.* 2009;131(2):021010.
55. Wahlgren NG, Lindquist C. Haem derivatives in the cerebrospinal fluid after intracranial haemorrhage. *Eur Neurol.* 1987;26(4):216-21.
56. Cruickshank AM. ACP Best Practice No 166: CSF spectrophotometry in the diagnosis of subarachnoid haemorrhage. *J Clin Pathol.* 2001;54(11):827-30.
57. Defrise M, Gullberg GT. Image reconstruction. *Phys Med Biol.* 2006;51(13):R139-54.
58. Watts R, Steinklein JM, Waldman L, Zhou X, Filippi CG. Measuring Glymphatic Flow in Man Using Quantitative Contrast-Enhanced MRI. *AJNR Am J Neuroradiol.* 2019;40(4):648-51.
59. Menendez Gonzalez M. Implantable Systems for Continuous Liquorpheresis and CSF Replacement. *Cureus.* 2017;9(2):e1022.
60. Baledent O, Gondry-Jouet C, Meyer ME, De Marco G, Le Gars D, Henry-Feugeas MC, et al. Relationship between cerebrospinal fluid and blood dynamics in healthy volunteers and patients with communicating hydrocephalus. *Invest Radiol.* 2004;39(1):45-55.
61. Blitz AM, Shin J, Baledent O, Page G, Bonham LW, Herzka DA, et al. Does Phase-Contrast Imaging through the Cerebral Aqueduct Predict the Outcome of Lumbar CSF Drainage or Shunt Surgery in Patients with Suspected Adult Hydrocephalus? *AJNR Am J Neuroradiol.* 2018;39(12):2224-30.
62. Dreha-Kulaczewski S, Joseph AA, Merboldt KD, Ludwig HC, Gartner J, Frahm J. Inspiration is the major regulator of human CSF flow. *J Neurosci.* 2015;35(6):2485-91.

63. Takizawa K, Matsumae M, Sunohara S, Yatsushiro S, Kuroda K. Characterization of cardiac- and respiratory-driven cerebrospinal fluid motion based on asynchronous phase-contrast magnetic resonance imaging in volunteers. *Fluids Barriers CNS*. 2017;14(1):25.
64. Yildiz S, Thyagaraj S, Jin N, Zhong X, Heidari Pahlavian S, Martin BA, et al. Quantifying the influence of respiration and cardiac pulsations on cerebrospinal fluid dynamics using real-time phase-contrast MRI. *J Magn Reson Imaging*. 2017;46(2):431-9.
65. Pizzichelli G, Kehlet B, Evju O, Martin BA, Rognes ME, Mardal KA, et al. Numerical study of intrathecal drug delivery to a permeable spinal cord: effect of catheter position and angle. *Comput Methods Biomech Biomed Engin*. 2017:1-10.

List of Figures

FIGURE 1. Overview of in vitro and numerical model based on subject specific MRI measurements. (a) T2-weighted MR image of the entire CSF space for the human analyzed to acquire subject-specific anatomy and natural CSF pulsations. (b) An in vitro bench-top model of the human CSF filled spaces was generated from MRI images, (b1-2) In vitro model spinal canal including nerve roots and cauda equina. (c) computational model of the human central nervous system (c1) Magnification of the cranial SAS consisting of lateral ventricles, foramen Monro (left and right), third ventricle, aqueduct of Sylvius, 4th ventricle, foramen Luschka, cisterna magna, pre-pontine and pontine cistern, trigeminal cistern, quadrigeminal cistern, Sylvian cisterns (left and right), and cortical subarachnoid space. (c2) Volumetric and surface mesh visualization with prism layers near the wall.

FIGURE 2. Schematic of the Neurapheresis system and study protocol (a) Three-dimensional CFD model of the SAS with flow boundary conditions and magnified view of the Neurapheresis catheter return and aspiration ports. (b) Oscillatory pump to induce CSF pulsations to match the CSF flow field acquired by phase contrast-MRI.

FIGURE 3. Hydrodynamic and geometric characterization of the computational domain. (a) Hydraulic diameter (Left axis) and Womersley number (Right axis), (b) Mean velocity, (c) cross-sectional area, (d) cross-sectional perimeter, and (e) Reynolds number.

FIGURE 4. Quantification of steady-streaming velocities. Steady-streaming within the spinal SAS increases with Neurapheresis therapy compared to lumbar drain. (a) Coronal view of cyclic mean z-velocity profiles, U_{z-mean} , in the cranial SAS is nearly identical for Neurapheresis therapy

and lumbar drain. (b) Sagittal view of cyclic mean z-velocity profiles, U_{z-mean} , simulated by CFD for lumbar drain (left) and Neurapheresis therapy (right). (c) Steady-streaming velocity magnitude, U_{ss} , and (d) non-dimensional fraction of flow rate amplitude, Q_{ss} .

FIGURE 5. Cross-sectional average tracer concentration over 24-hours. (a) Neurapheresis therapy and (b) lumbar drain. (a1) Cross-sectional average tracer concentration plotted with respect to time at specific axial locations under Neurapheresis therapy. (a2) Cross-sectional average tracer concentration along the neuroaxis for different time points, $t = 0, 1, 6, 12$, and 24 hours under Neurapheresis therapy. (a3) spatial temporal plot for cross-sectional average tracer concentration for CFD and in-vitro under Neurapheresis therapy along the model for 24-hours. (b1) Cross-sectional average tracer concentration plotted with respect to time at specific axial locations under lumbar drain. (b2) Average tracer concentration along the neuroaxis for different time points, $t = 0, 1, 6, 12$, and 24 hours under lumbar drain. (b3) spatial temporal plot for cross-sectional average tracer concentration for CFD and in-vitro under lumbar drain along the model for 24-hours.

FIGURE 6. CFD results for 2D tracer concentration profiles versus time under Neurapheresis therapy and lumbar drain. (a) Visualization of tracer concentration at 0, 1, 6, 12, and 24 hours under Neurapheresis therapy, and (b) Visualization of tracer concentration at 1, 6, 12, and 24 hours under lumbar drain.

FIGURE 7. Correlation and Bland-Altman plots for agreement of in vitro and numerical simulation results for spatial-temporal cross-sectional average tracer concentration over 24-hours. (a) Neurapheresis therapy and (b) lumbar drain. The linear regression is shown in

948 black dashed line (left subplots, a1 and b1) and the limit of agreement (95% confidence intervals)
949 lines are shown in dashed lines (right subplots, a2 and b2).
950

Figures

Figure 1

Figure legends available in the PDF

Figure 2

Figure 3

Figure 4

U_{ss} , and (d) non-dimensional fraction of flow rate amplitude, Q_{ss} .

(a) Neurapheresis therapy

(b) Lumbar drain

Figure 5

Figure 6

Cross-sectional average tracer concentration (%)

(a) Neurapheresis therapy

(b) Lumbar drain

Figure 7